99¦~10¤ë¸¹ ¹D ªk ªk °T (222)

DEEP & FAR

 

 

¬y¦æ¯f¾Ç¦]ªGÃö«Y¤§±Òµo

 

 

±i¬f²W «ß®v

¡D¬Fªv¤j¾Çªk«ß¾Ç¨t¾Ç¤h

¡D¬Fªv¤j¾Çªk«ß¾Ç¬ã¨s©ÒºÓ¤h

¡D«ß®v°ª¦Ò¤Î®æ

 

 

²Ä¤T¸`¡@¬ü°êªk°|¦p¦ó¥H¬ì¾ÇÃÒ¾Ú»{©w¦]ªGÃö«Y¯B¤ô¦L

²Ä¤G¶µ        ¬Û¹ï¦MÀI«×»P¦]ªGÃö«Y

 

 ²Ä¤G´Ú¡@¾Ç»¡¨£¸Ñ

 

3. Âk¦]­·ÀI¡BÂk¦]¤ñ¨Ò¥¼±N¿©¯fªº®É¶¡ÂI¯Ç¤J¦Ò¶q¡C
Á|¨Ò»¡©ú¦p¤U¡A±µÄ²©ñ®g½u¤§¸sÅéa¤§¿©Àù¤ñ²v¬O¤d¤À¤§¤Q¡A¥¼±µÄ²©ñ®g½u¤§¸sÅéb¤§¿©Àù¤ñ²v¬O¤d¤À¤§¤G¡A¸Ó¤d¤À¤§¤G¤§¤ñ²v¬O¥Ñ¨ä¥L¦]¯À³y¦¨¡A¥ç§Y»P±µÄ²©ñ®g½uµLÃöªº­I´º­·ÀI¡]background risks¡^¡F±N¥¦¦©°£«á¡A³Ñ¾lªº¤d¤À¤§¤K§Y¬°»P±µÄ²©ñ®g½u¦³Ãöªº¿©Àù¤ñ²v¡A³QºÙ¬°Âk¦]­·ÀI¡A±µµÛ¦A¥H¦¹¬°°ò¦­pºâÂk¦]¤ñ²v¡C
°ÝÃD¬O¡A¥H¤Wªº­pºâ¹Lµ{§¹¥þ¨S¦³±N¿©¯fªº®É¶¡ÂI¯Ç¤J¦Ò¶q¡C¦p¸sÅébªº¿©Àù¤ñ²v¬O¤d¤À¤§¤G¡A³o¤d¤À¤§¤Gªº¤H¿©±wÀù¯gªº®É¶¡¥­§¡¬O¤»¤Q·³¡F¥t¤@¸sÅéa¿©Àùªº¤ñ²v¬O¤d¤À¤§¤Q¡A³o¤d¤À¤§¤Qªº¤H¿©Àùªº®É¶¡¥­§¡¬O¦b¤T¤Q·³¡C¦¹®É¬O§_¤´¥i¾A¥Î¤W­z­pºâ¤è¦¡¡A±Na¸sÅ餤¤d¤À¤§¤G¤§¿©Àù¤ñ²v¦©°£¡H
¤W­z¤§­pºâ¤è¦¡¡]¤d¤À¤§¤Q´î¥h¤d¤À¤§¤G¡^¬Oªí¥Ü¤d¤À¤§¤Gªº¿©Àù¤ñ²v­ì¥»µL½×¦p¦ó³£·|µo¥Í¡A»P±µÄ²©ñ®g½uµLÃö¡A©Ò¥H±N¤§¦©°£¡CµM¦Ó¡Aa¸sÅ餧¿©ÀùªÌ¿©Àù¤§®É¶¡ÂI¥­§¡¬°¤T¤Q·³¡A¬O§_ÁÙ¥i¥H»{¬°¦³¤d¤À¤§¤Gªº¿©Àù¤ñ²v»P±µÄ²©ñ®g½uµLÃö¡H¡]­Y»P±µÄ²©ñ®g½uµLÃö¡A¥¿±`ªº¿©Àù®É¶¡ÂI¥­§¡¬O¦b¤»¤Q·³¡^¡C
µª®×®£©È­È±o°Óºe¡C»\¤d¤À¤§¤Gªº¤H­Y¨S¦³±µÄ²©ñ®g½u¡A¨ä¥Í¦s´Á¶¡¤£·|³Q¤j´TÁYµu¡]¥Ñ¥¿±`µo¥ÍÀù¯g¤§¤»¤Q·³³Q´£«e¦Ü¤T¤Q·³¡^¡FÀ³»{¬°¨ä¿©Àù®ÉÂI³Q´£«e¡]accelerated¡^»P±µÄ²©ñ®g½u¦³Ãö¡A¦]¦¹¤£À³±N¦¹³¡¤À·í§@¬OµL½×¦p¦ó·|µo¥Í¤§­I´º­·ÀI¡F ©Ò¥H¥¿½TªºÂk¦]­·ÀI¬O¤d¤À¤§¤Q¡A¦ÓÂk¦]¤ñ²vÀ³¸Ó¬O¦Ê¤À¤§¦Ê¡C¥Ñ©ó¤@¯ëªº¬y¦æ¯f¾Ç¬ã¨s¦b­pºâÂk¦]­·ÀI¡BÂk¦]¤ñ²v®É¨Ã¥¼§@¤W­z®É¶¡ÂI¤§¦Ò¶q¡A¦]¦¹¬ã¨sµ²ªG¤§¥i¾a©Ê¤´¦³ºÃ°Ý¡C

4. ¬Û¹ï¦MÀI«×2.0 ¥H¤W¤§ªùÂe»P¬ì¾Ç¬É¹ê°È¨Ã¤£¤@­P¡C
Daubert
®×¤¤³Ì°ªªk°|»{¬°¡A¬ì¾Ç¬ã¨sµ²ªG¡B±M®aÃÒ¨¥¥²¶·¨ã³ÆÃöÁp©Ê¡A¥H¤Î¥i¾a¡B½T¹ê©Ê¡A©l¥i³Q©Ó»{¡C¦Ó¥i¾a¡B½T¹ê©Ê«h¥²¶·­n¥H¬ì¾Ç¤W¤§¦³®Ä©Ê¡]Scientific validity¡^§@¬°§PÂ_¼Ð·Ç¡C­Y½T¹ê¿í·ÓDaubert§P¨M¤§«ü¥Ü¡Aªk°|©ó¨M©w¬O§_©Ó»{¬ì¾ÇÃҾڮɡAÀ³¸Ó¨Ì¾Ú¬ì¾Ç¬É¤§¼Ð·Ç¨M©w¸ÓÃÒ¾Ú¬O§_¬ÛÃö¥H¤Î¦³®Ä¡C
©Ò¥H¬ì¾Ç¬É©ó§PÂ_¦]ªGÃö«Y®É¡A¤´­n¨D¦h¤è¤ñ¸û¤£¦Pªº¸ê°T¨Ó·½¡F ¨Ò¦p¡AÁ{§ÉÂå®vªºÃÒ¨¥¡BŲ§O¶EÂ_¡]Differential diagnosis¡^¡B°Êª«¹êÅçµ²ªG¡B­ì§i¤§²Õ´²Ó­M±Ä¼Ë¤ÀªR¡B¥H¤Î­ì§i¤§¯S®íÅé½è¡B®a±Ú¯f¥vµ¥µ¥¡F¹L¥÷¦a¥õ¿à³æ¤@ªº¬ì¾Ç¤èªk¬O»P¬ì¾Ç¹ê°È¬Û­IÂ÷ªº¡C
¦AªÌ¡A§Y¨Ï­n¨D­ì§i´£¥X¬y¦æ¯f¾Ç¬ã¨s¬O¦X²zªº¡A¦ý¬Û¹ï¦MÀI«×2.0¥H¤W¤§ªùÂe¤´¥¼¨£¦X²z¡C¨Æ¹ê¤W¡A¬Û¹ï¦MÀI«×¥u­n¦b1.0¥H¤W¡A´Nªí¥Ü¸Ó¯S©wª«½è¦³´£°ª­·ÀI¡B³y¦¨·l®`ªº¯à¤O¡F¥¿¦p·s­^®æÄõÃľÇÂø»x¡]New England Journal of Medicine¡^ªº°õ¦æ½s¿èMarcia Angell³Õ¤h©Ò¨¥¡A·í¤@¶µÃö©ó¶©¨Å¤§¬y¦æ¯f¾Ç¬ã¨s¡]±´°Q¶©¨Å»P§_¹ï©ó°ü¤k¦Û¨­§K¬Ì¨t²Î¯e¯f¤§¼vÅT¡^Åã¥Ü¥X1.24ªº¬Û¹ï¦MÀI«×®É¡Fªí¥Ü¸Ó¶©¨Åªº¦æ¬°¡]©Î¬O¶ñ¥R¤J¯Ý³¡¤§¯S©wª«½è¡^¨Æ¹ê¤W¤´³y¦¨¤F¬Y¨Ç°ü¤kªº¯e¯f¡]¦Û¨­§K¬Ì¨t²Î¯e¯fauto-immune disease¡^¡C1.24¤§¬Û¹ï¦MÀI«×ªí¥Ü¡A¦b¤Q¤G­Ó¶©¨Å¦Ó²£¥Í§K¬Ì¨t²Î¯e¯fªº°ü¤k¤¤¡A¤j¬ù¦³2­Ó°ü¤k¤§§K¬Ì¨t²Î¯e¯f§¹¥þ¬O¥Ñ¶©¨Å©Ò³y¦¨¡C¥Ñ¦¹¥iª¾¡A§Y¨Ï¬Û¹ï¦MÀI«×¦b2.0¥H¤U¡A§@¬°¬ã¨s¥DÃD¤§¯S©wª«½è©Î¦æ¬°¤´µM¦³¥i¯à³y¦¨¯S©w¤H¤§¯e¯f©Î¶Ë®`¡F¤£¯à¥u¦]¬°¾ãÅ饭§¡¦MÀI¨S¦³¹F¨ìªk°|­n¨D¤§ªùÂe¡A§Y©¿µø¸Óª«½è¹ï¯S©w­Ó¤H±a¨Ó¶Ë®`¤§¥i¯à©Ê¡C